Castle Biosciences(us:CSTL)
19.78
-1.20%
Updated on 2025-04-02
Open:20.00
Close:19.78
High:20.22
Low:19.34
Prev Close:20.02
Volume:244269.00
Turnover:4.84M
Turnover Ratio:0.86%
Shares:28.51M
MarketCap:564.01M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 177 | 25150451 | 90.76% | 31 | 54 | 69 |
| 2024-03-31 | 166 | 24921302 | 90.34% | 19 | 54 | 71 |
| 2023-12-31 | 169 | 23811362 | 86.87% | 35 | 56 | 63 |
| 2023-09-30 | 148 | 23084561 | 85.85% | 22 | 52 | 55 |
| 2023-06-30 | 160 | 22962020 | 85.73% | 18 | 68 | 58 |
| 2023-03-31 | 161 | 21986679 | 82.39% | 15 | 63 | 53 |
| 2022-12-31 | 180 | 22725755 | 85.58% | 23 | 51 | 82 |
| 2022-09-30 | 171 | 21720422 | 82.43% | 24 | 57 | 61 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Blackrock Inc. | 2595687 | 9.41% | 312488 | 13.69% |
| 2024-03-31 | Wasatch Advisors Lp | 2551088 | 9.25% | -39863 | -1.54% |
| 2024-03-31 | Granahan Investment Management, Llc | 1627224 | 5.90% | -539247 | -24.89% |
| 2024-03-31 | Principal Financial Group Inc | 1532472 | 5.56% | -53201 | -3.35% |
| 2024-03-31 | Vanguard Group Inc | 1494176 | 5.42% | 32695 | 2.24% |
| 2024-03-31 | Bellevue Group Ag | 1220085 | 4.42% | -12293 | -1.00% |
| 2024-03-31 | Portolan Capital Management, Llc | 1043410 | 3.78% | 314757 | 43.20% |
| 2024-03-31 | Deerfield Management Company, L.P. (Series C) | 928017 | 3.36% | -37411 | -3.88% |
| 2024-03-31 | Dimensional Fund Advisors Lp | 749259 | 2.72% | 85377 | 12.86% |
| 2024-03-31 | Soleus Capital Management, L.P. | 725457 | 2.63% | 699457 | 2690.22% |
About
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Address:505 South Friendswood Drive,Suite 401
Website:http://www.castlebiosciences.com
Market Movers